Last reviewed · How we verify

Prevention of Venous Thromboembolism

Prof. Stavros Konstantinides, MD · Phase 3 active Small molecule

Prevention of Venous Thromboembolism is a Anticoagulant Small molecule drug developed by Prof. Stavros Konstantinides, MD. It is currently in Phase 3 development for Prevention of venous thromboembolism in patients undergoing major orthopedic surgery. Also known as: Rivaroxaban, Xarelto, anticoag, Direct oral anticoagulant.

This drug prevents the formation of blood clots in the veins by inhibiting the coagulation cascade.

This drug prevents the formation of blood clots in the veins by inhibiting the coagulation cascade. Used for Prevention of venous thromboembolism in patients undergoing major orthopedic surgery.

At a glance

Generic namePrevention of Venous Thromboembolism
Also known asRivaroxaban, Xarelto, anticoag, Direct oral anticoagulant, DOAC
SponsorProf. Stavros Konstantinides, MD
Drug classAnticoagulant
TargetFactor Xa
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

It does this by targeting and inhibiting the activity of Factor Xa, a key enzyme in the coagulation pathway. This leads to a reduction in the formation of thrombin, which is essential for blood clot formation. As a result, the risk of venous thromboembolism is decreased.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Prevention of Venous Thromboembolism

What is Prevention of Venous Thromboembolism?

Prevention of Venous Thromboembolism is a Anticoagulant drug developed by Prof. Stavros Konstantinides, MD, indicated for Prevention of venous thromboembolism in patients undergoing major orthopedic surgery.

How does Prevention of Venous Thromboembolism work?

This drug prevents the formation of blood clots in the veins by inhibiting the coagulation cascade.

What is Prevention of Venous Thromboembolism used for?

Prevention of Venous Thromboembolism is indicated for Prevention of venous thromboembolism in patients undergoing major orthopedic surgery.

Who makes Prevention of Venous Thromboembolism?

Prevention of Venous Thromboembolism is developed by Prof. Stavros Konstantinides, MD (see full Prof. Stavros Konstantinides, MD pipeline at /company/prof-stavros-konstantinides-md).

Is Prevention of Venous Thromboembolism also known as anything else?

Prevention of Venous Thromboembolism is also known as Rivaroxaban, Xarelto, anticoag, Direct oral anticoagulant, DOAC.

What drug class is Prevention of Venous Thromboembolism in?

Prevention of Venous Thromboembolism belongs to the Anticoagulant class. See all Anticoagulant drugs at /class/anticoagulant.

What development phase is Prevention of Venous Thromboembolism in?

Prevention of Venous Thromboembolism is in Phase 3.

What are the side effects of Prevention of Venous Thromboembolism?

Common side effects of Prevention of Venous Thromboembolism include Major bleeding, Gastrointestinal bleeding, Hemorrhage.

What does Prevention of Venous Thromboembolism target?

Prevention of Venous Thromboembolism targets Factor Xa and is a Anticoagulant.

Related